HK1192231A1 - Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use thereof -iv i - Google Patents

Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use thereof -iv i

Info

Publication number
HK1192231A1
HK1192231A1 HK14105514.0A HK14105514A HK1192231A1 HK 1192231 A1 HK1192231 A1 HK 1192231A1 HK 14105514 A HK14105514 A HK 14105514A HK 1192231 A1 HK1192231 A1 HK 1192231A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
salt
preparation
crystal form
dipeptidyl peptidase
Prior art date
Application number
HK14105514.0A
Other languages
English (en)
Chinese (zh)
Inventor
舒楚天
Original Assignee
山東軒竹醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山東軒竹醫藥科技有限公司 filed Critical 山東軒竹醫藥科技有限公司
Publication of HK1192231A1 publication Critical patent/HK1192231A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK14105514.0A 2011-07-09 2014-06-11 Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use thereof -iv i HK1192231A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110202157 2011-07-09
PCT/CN2012/078294 WO2013007167A1 (fr) 2011-07-09 2012-07-06 Forme cristalline i d'un sel d'un inhibiteur de dipeptidyl-peptidase-iv, son procédé de préparation et son utilisation

Publications (1)

Publication Number Publication Date
HK1192231A1 true HK1192231A1 (en) 2014-08-15

Family

ID=47442601

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14105514.0A HK1192231A1 (en) 2011-07-09 2014-06-11 Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use thereof -iv i

Country Status (7)

Country Link
US (1) US8927572B2 (fr)
EP (1) EP2730575B1 (fr)
JP (1) JP5695800B2 (fr)
CN (1) CN102863440B (fr)
ES (1) ES2547687T3 (fr)
HK (1) HK1192231A1 (fr)
WO (1) WO2013007167A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017107945A1 (fr) * 2015-12-24 2017-06-29 山东轩竹医药科技有限公司 Forme cristalline de benzoate d'inhibiteur de dipeptidyl peptidase-iv
WO2017211293A1 (fr) * 2016-06-08 2017-12-14 山东轩竹医药科技有限公司 Forme cristalline du succinate servant d'inhibiteur de la dipeptidyl peptidase-4

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
EP1568699A4 (fr) * 2002-12-04 2007-08-15 Eisai R&D Man Co Ltd Compose 1,3-dihydro-imidazole a cycle fusionne
CN101228164A (zh) * 2005-05-20 2008-07-23 布里斯托尔-迈尔斯·斯奎布公司 二肽基肽酶iv的吡咯并吡啶类抑制剂及方法
US7521557B2 (en) * 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物

Also Published As

Publication number Publication date
EP2730575B1 (fr) 2015-09-16
CN102863440B (zh) 2015-05-27
US8927572B2 (en) 2015-01-06
US20140206874A1 (en) 2014-07-24
JP5695800B2 (ja) 2015-04-08
ES2547687T3 (es) 2015-10-08
EP2730575A1 (fr) 2014-05-14
CN102863440A (zh) 2013-01-09
WO2013007167A1 (fr) 2013-01-17
JP2014520763A (ja) 2014-08-25
EP2730575A4 (fr) 2014-11-26

Similar Documents

Publication Publication Date Title
EP2726075A4 (fr) Nouvelles formes cristallines d'un inhibiteur de peptidase-iv
PL2863918T3 (pl) Kryształy soli inhibitora pde1
HK1174114A1 (en) Representation of people in a spreadsheet
ZA201308065B (en) Combinations of akt inhibitor compounds and vemurafenib and methods of use
ZA201303433B (en) Inhibitors of hiv replication
EP2748407A4 (fr) Outil de fond et procédé d'utilisation
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
IL270748B (en) Preparations containing a substance with anticoxinic activity and their use to increase the activity of acetylcholinesterase inhibitors
EP2709993A4 (fr) Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron
HK1202628A1 (en) Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor tnf-
EP2697422A4 (fr) Composition et procédé pour former une surface autodécontaminante
HK1201524A1 (zh) 激酶抑制劑及治療相關疾病的方法
EP2743261A4 (fr) Forme cristalline i de racémate de 4-hydroxy-2-oxo-1-pyrrolidine-acétamide et procédé de préparation de celle-ci
GB201101810D0 (en) A method of connecting meshes
EP2844271A4 (fr) Procédé de traitement et agents utiles pour celui-ci
WO2012145254A9 (fr) Procédés d'utilisation d'inhibiteurs de rorϒt pour traiter une maladie
PL2760271T3 (pl) Prasa do bel i sposób czyszczenia prasy do bel
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
SG10201405403QA (en) Novel salts of dpp-iv inhibitor
EP2717869A4 (fr) Méthodes de traitement à l'aide d'un inhibiteur de bcat1
HK1176675A1 (zh) 形成用於裝置中的增強表面壁的方法
EP2663574A4 (fr) Inhibiteurs de réplication rétrovirale
HK1192231A1 (en) Crystal form i of salt of a dipeptidyl peptidase-iv inhibitor and preparation method and use thereof -iv i
EP2729468A4 (fr) Hétérocycles tricycliques utiles comme inhibiteurs de la dipeptidyl peptidase-iv
EP2681199A4 (fr) Procédés de fabrication de (--)- huperzine a, compositions associées, et méthodes de traitement

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190704